Dianthus Therapeutics, Inc. (DNTH)
Nasdaq: DNTH · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 9, 2026 | Mar 11, 2025 | Mar 21, 2024 | Mar 23, 2023 | Mar 8, 2022 | Mar 3, 2021 | Mar 3, 2020 | Mar 19, 2019 | · | · |
| Revenue | 2,036 | 6,235 | 2,826 | · | · | · | 0 | 0 | 0 | 0 |
| For lenders | ||||||||||
| Interest and dividend income | 16,119 | 17,365 | 4,764 | · | · | · | · | · | · | · |
| Interest and investment income | 9,956 | 11,347 | 3,341 | 1,145 | · | · | · | · | · | · |
| Research and development | 145,638 | 83,105 | 32,841 | 29,379r | 46,766 | 50,615 | 59,208 | 41,340 | 27,899 | 5,782 |
| General and administrative | 34,331 | 24,994 | 18,159 | 6,743r | 27,926 | 28,087 | 23,761 | 18,623 | 7,828 | 3,486 |
| Total operating expenses | 179,969 | 108,099 | 51,000 | 36,122r | 74,692 | 78,702 | 82,969 | 59,963 | 35,727 | 9,268 |
| Operating income | -177,933 | -101,864 | -48,174 | -29,705r | -74,692 | -78,702 | -82,969 | -59,963 | -35,727 | -9,268 |
| Interest expense | · | · | · | · | · | · | · | · | · | 163 |
| Other income (expense), net | -974 | -554 | -60 | -52 | · | · | · | · | · | · |
| Total non-operating income (expense) | 15,596 | 16,895 | 4,619 | 1,229 | · | · | · | 2,448 | 236 | -163 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | -162,337 | -84,969 | -43,555 | -28,476r | -71,136 | -74,936 | -76,769 | -57,515 | -35,491 | -9,431 |
| Net income | -162,337 | -84,969 | -43,555 | -28,476r | -71,136 | -74,936 | -76,769 | -57,515 | -35,491 | -9,431 |
| Net income to common shareholders | · | · | · | · | · | · | -76,769 | -57,603 | -35,507 | -9,735 |
| Earnings per share, basic | -4.20 | -2.55 | -8.45 | -32.57r | -1.29 | -1.71 | · | · | · | · |
| Earnings per share, diluted | -4.20 | -2.55 | -8.45 | -32.57r | -1.29 | -1.71 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -1.71 | -2.07 | -3.13 | -19.12 | -65.15 |
| Weighted average shares, basic | 38,617,580 | 33,313,849 | 5,153,423 | 874,234r | 54,948,808 | 43,920,121 | · | · | · | · |
| Weighted average shares, diluted | 38,617,580 | 33,313,849 | 5,153,423 | 874,234r | 54,948,808 | 43,920,121 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 43,920,121 | 37,014,875 | 18,389,576 | 1,856,907 | 149,414 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InterestIncomeOtherResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted